A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction

Trial Profile

A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Acronyms ARIANA-CHF-RD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2015 Results published in the American Heart Journal.
    • 16 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top